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inTRODUCTiOn
Acute community-acquired respiratory tract infections
(CARTi), one of the principal causes of morbidity and mortality
in the world,1 are the primary cause of antibiotic use. Antimi-
crobial therapy of respiratory tract infections is generally em-
piric, both due to the severity of the disease (community-
acquired pneumonia, CAP) that requires early therapy, and due
to the difficulty of establishing a microbial etiology, as in the
polymicrobial forms of acute or chronic otitis media, and in
acute exacerbations during chronic bronchitis and sinusitis.2
While the community-acquired infectious etiology has not re-
ally changed over time, antibiotic resistance complicates treat-
ment which then leads to therapeutic failure, relapse, prolonged
symptoms and hospital stay, as well as increasing costs.
since the 1980s there has been decreased sensitivity among
all the respiratory pathogens to various antimicrobial drugs. The
production of beta-lactamases occurs more frequently in
Haemophilus influenzae and Moraxella catarrhalis, but
Streptococcus pneumoniae can be resistant to beta-lactams
and macrolides too.3,4,5,6 The resistance to third-generation
cephalosporins, with or without concomitant resistance to peni-
cillin, is particularly alarming.7
since the development of bacterial resistance to antibiotics
is a worldwide and multifactorial phenomenon, the mechanisms
and lack of sensitivity can vary among countries as well as re-
gions of the same country.2
To establish correct empiric therapy, reduce the develop-
ment of resistance and evaluate the potential use of new eradi-
cation strategies, it is necessary to have up-to-date data on the
frequency of resistance in different geographic areas as well as
on the activity of new antimicrobial drugs that are available to
physicians.
Over the last few years, antibiotic resistance observed in
pathogens responsible for CARTi has complicated the empiric
choice of antibiotic therapy, leading to the necessity of using re-
cent generation macrolides, cephalosporins, beta-lactam/beta-
lactamase-inhibitor combinations, or fluoroquinolones.8,9
Despite the fact that all these drugs have different degrees of
antimicrobial effectiveness, the new generation of oral
cephalosporins offers better advantages, such as improved spec-
trum, rapid bactericidal activity, low rates of spontaneous mu-
tation, extended post-antibiotic effect, and well-known safety
profiles.10-14
The recent introduction in italy of cefditoren pivoxil in 2008,
a third-generation oral cephalosporin, active against both Gram-
positive (S. pneumoniae, Streptococcus pyogenes and Staphy-
lococcus aureus, MssA), and Gram-negative (H. influenzae
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Summary
the aim of this study was to evaluate the invitro an-
tibiotic susceptibility of respiratory pathogens recently iso-
lated in italy to commonly used antibiotics including
cefditoren. Six clinical microbiological laboratories col-
lected, between January and September 2009, a total of
2,510 respiratory pathogens from subjects with commu-
nity-acquired respiratory tract infections (CARti). Cefdi-
toren, out of all the beta-lactams studied, had the lowest
miC
90
against 965 strains of Streptococcuspneumoniae
examined, followed by cefotaxime and ceftriaxone (2% re-
sistance in penicillin-resistant S.pneumoniae (pRSp)).
Against 470 Haemophilusinfluenzae, independently of
their production of beta-lactamases or ampicillin resist-
ance, cefditoren was the oral cephalosporin with the best
in vitro activity, comparable to that of the injectable
cephalosporins and levofloxacin. Higher miC
90
s were
found for the macrolides (4 - 16 mg/l) and cefaclor (4 - 32
mg/l). As was foreseeable, Streptococcuspyogenes (225
strains) was uniformly sensitive to all the beta-lactam an-
tibiotics, but the elevated miC
90
values reduced (<75%)
susceptibility of this pathogen to macrolides. beta-lacta-
mase-negative Moraxellacatarrhalis (100 strains) had re-
duced susceptibility only to the macrolides, while the 250
beta-lactamase-producing strains also had reduced suscep-





values in the producing strains, whereas
cefditoren, cefotaxime and ceftriaxone in the non-produc-
ers. As regards the enterobacteriaceae, cefditoren and lev-
ofloxacin had the lowest miC
90
s against Klebsiella
pneumoniae. Cefditoren and the third-generation in-
jectable cephalosporins had the lowest miC
90
s against Es-
cherichiacoli (100% susceptibility) while levofloxacin was
less active (86% susceptibility). 
in conclusion, cefditoren’s wide spectrum and high in-
trinsic activity, as well as its capacity to overcome most of
the resistance that has become consolidated in some
classes of antibiotics widely used as empiric therapy for
CARti, allows us to suggest that cefditoren might be in-
cluded in the european guidelines as one of the first-choice
antibiotics in the treatment of CARti.
Keywords: Cefditoren, respiratory pathogens, suscep-
tibility patterns, epidemiological study.
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and M. catarrhalis) bacteria,10,12-13,15 and thus indicated in the
treatment of acute pharyngotonsillitis, acute maxillary sinusitis,
acute exacerbations of chronic bronchitis, and slight to moder-
ate CAP, is of particular interest.15-20
Cefditoren’s antimicrobial mechanism of action, common to
all cephalosporins, consists in its inhibition of cell-wall synthesis
thanks to its affinity for PBPs. However, its unique structure at
the C-3 side chain of its cephem skeleton has been correlated
with higher intrinsic activity against S. pneumoniae, both sus-
ceptible and resistant to penicillin (PssP and PRsP).21-22
Administered orally, cefditoren pivoxil is absorbed in the gas-
trointestinal tract and then the active component cefditoren is
hydrolyzed by plasmatic esterases.23
The good in vitro activity of cefditoren has been confirmed
by numerous studies carried out over the last 10 years world-
wide24,25, and recently in more than 2,000 respiratory
pathogens in italy in 2008.26
The aim of this study was to evaluate the antibiotic suscep-
tibility of respiratory pathogens recently isolated in italy and to
investigate their in vitro susceptibility to cedfditoren. Moreover,




six clinical microbiological laboratories uniformly distributed
in italy [Lombardy (420 strains), Piedmont (380 strains), Veneto
(440 strains), The Marches (380 strains), Campania (440
strains) and sicily (450 strains)] participated in this study. Each
laboratory isolated bacterial strains from subjects with CARTi
during the period January to september, 2009, and sent them
to the coordinating center (Dept. of Microbiological sciences,
University of Catania). 
Bacterial strains
A total of 2,510 respiratory pathogens were collected and
identified: 965 strains of S. pneumoniae (of which 650 peni-
cillin susceptible (PssP), 215 intermediate (PisP), and 100 re-
sistant (PRsP)), 470 strains of H. influenzae, of which 200
produce beta-lactamase and 20 beta-lactamase-negative ampi-
cillin-resistant (BLnAR), 350 strains of M. catarrhalis of which
250 produce beta-lactamases, 225 strains of S. pyogenes, 300
strains of oxacillin-susceptible S. aureus (MssA), 100 strains of
K. pneumoniae, and 100 strains of e. coli.
S. pneumoniae strains were isolated from the lower respi-
ratory tract (400), the upper respiratory tract (500), and blood
(65). 
H. influenzae and M. catarrhalis strains were isolated from
the lower respiratory tract (85, 47) and from the upper respi-
ratory tract (385, 303). K. pneumoniae and e. coli were iso-
lated from the lower respiratory tract. The isolates were
identified by means of Gram staining, growth on specific and se-
lective media, colony morphology and biochemical tests (Bio-
merieux).
Antibiotics
Antimicrobial agents including oral cephalosporins (cefaclor,
cefuroxime, cefixime, ceftibuten, cefpodoxime and cefditoren)
and injectable cephalosporins (ceftriaxone and cefotaxime),
penicillins (penicillin, amoxicillin, amoxi/clavulanate, ampicillin),
macrolides (azithromycin and clarithromycin), and a fluoro-
quinolone (levofloxacin) were tested against the bacterial iso-
lates. The drugs were purchased from sigma Aldrich or
obtained as a gift from their manufacturer.
Antibiotic susceptibility test
susceptibility testing was performed by broth microdilution
test, according to the guidelines of the Clinical Laboratory stan-
dards institute (CLsi) 2008 (M100-s18)27 and 2006 (M45-A)
for M. catarrhalis.28
As there are no approved CLsi breakpoints for cefditoren
against S. pneumoniae, H. influenzae, M. catarrhalis, MssA
and K. pneumoniae, the breakpoints reported by Lee et al. (R
≥2 mg/L) were used.29
The following strains were used to evaluate quality control:
S. pneumoniae ATCC 49619; H. influenzae ATCC 49247
and ATCC 49766; S. aureus ATCC 29213; e. coli ATCC
25922 and ATCC 35218.
The protocol of this study has been approved by the GiARiR
(Gruppo italiano per lo studio delle Antibiotico resistenze
nelle infezioni respiratorie) board.
REsULTs
This study included a total of 2,510 bacterial strains collected
from community-acquired infections of the respiratory tract in
the period between January and september, 2009, in italy. 
The results of the in vitro activity of cefditoren against seven
respiratory pathogens are shown in tables 1-7, while a com-
parison (MiC90) with 14 other antimicrobial agents is summa-
rized in table 8.
S. pneumoniae strains (table 1) are distributed in three phe-
notypic groups: susceptible, intermediate, and resistant, using,
for penicillin, the breakpoints (CLsi 2008 - M100-s18) relative
to parenteral administration against strains not responsible for
meningitis. Cefditoren had the lowest MiC90 against S. pneu-
moniae of all the comparator drugs. According to the break-
points suggested by Lee et al.,29 cefditoren was the only
antibiotic active against 100% of the strains examined, followed
by the third-generation injectable cephalosporins (cefotaxime
and ceftriaxone) (2% resistance in PRsP). 
All antimicrobial agents examined demonstrated good activ-
ity against PssP, with the exception of azithromycin and clar-
ithromycin (15.4% of resistance); in terms of MiC values
cefditoren showed excellent activity in comparison with the
other beta-lactam antibiotics (cefixime and cefaclor:
MiC50/MiC90 less than 4-5 times). 
Penicillin-intermediate (PisP) strains were resistant to cefa-
clor (74.4%) and cefuroxime (21.86%). Cefpodoxime showed
18.14% resistance, and levofloxacin 2.33%. Furthermore,
38.6% and 39.54% of strains were resistant to azithromycin
and clarithromycin, respectively. Also in this case cefditoren
showed the lowest MiC50/MiC90 values.
Penicillin-resistant strains showed a high percentage of re-
sistance against oral cephalosporins, i.e. cefaclor (100%), ce-
furoxime (86%), cefpdoxime (88%), amoxicillin with/without
clavulanic acid (40%) and macrolides (45%-47%). Conversely,
low resistance was observed to injectable cephalosporins (2%)
and levofloxacin (3%). 
Ampicillin-resistant beta-lactamase-positive H. influenzae
strains (table 2) showed 20% resistance to cefaclor and BLnAR
10% resistance to amoxicillin/clavulanate. Of the oral
cephalosporins, cefditoren had the best in vitro activity, com-
parable to that of the injectable cephalosporins and levofloxacin.
Higher levels of MiC90 were found for the macrolides (4 - 16
mg/L) and cefaclor (4 - 32 mg/L).
Beta-lactamase-negative M. catarrhalis (table 3) showed re-
duced susceptibility to macrolides, while beta-lactamase-pro-
ducing strains had reduced susceptibility to cefuroxime.
Levofloxacin showed the lowest MiC50/MiC90 values against
beta-lactamase-producing strains, while cefditoren, cefotaxime
and ceftriaxone against non-beta-lactamase-producers.
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lactams; the MiC50/MiC90 values of cefditoren were compara-
ble, with the exception of cefaclor (>4 times) and of ceftibuten
(>3 times). The elevated MiC90 values found for azithromycin
and clarithromycin confirm the reduced susceptibility of this
pathogen to macrolides. 
87% of methicillin-sensitive S. aureus (MssA) (table 5)
were resistant to penicillin; 46% of the strains were also resist-
ant to macrolides, while only 2.66% showed reduced suscepti-
bility to levofloxacin. All the other tested antibiotics for which it
was possible to obtain the MiC breakpoints were found to be ac-
tive. According to the breakpoints suggested by Lee et al, cefdi-
toren showed good activity with MiC50/MiC90 similar to those of
amoxicillin/clavulanate and levofloxacin and much higher than
that of all other oral molecules of the same class.
As regards the Enterobacteriaceae, in particular K. pneu-
moniae (tables 6-7), cefditoren and levofloxacin showed the
lowest MiC90 values, even if, probably due to the presence of ex-
tended-spectrum beta-lactamase producing (EsBL) strains, bac-
teria resistant to all the antibiotics tested were detected. Both
cefditoren and the injectable cephalosporins were totally active
against e. coli, whereas levofloxacin had reduced activity (86%
susceptible). Cefditoren was the most active antimicrobial agent,
both in terms of MiC50 and MiC90 values.
TABLE 1 - in vitro activity of cefditoren and comparative antimicrobials agents against 965 isolates of S. pneumoniae grouped according
to their penicillin susceptibility pattern. 
Antimicrobial drug MIC (mg/L)
Penicillin susceptible (n= 650) Penicillin intermediate (n= 215 ) Penicillin resistant (n= 100 )
MiC50 MiC90 %i %R MiC50 MiC90 %i %R MiC50 MiC90 %i %R
Cefditoren* ≤0.015 0.03 0 0 0.06 0.5 0 0 0.25 0.50 0 0
Cefaclor 0.5 1.0 0 0 8 ≥64 5.6 74.4 ≥64 ≥64 0 100
Cefuroxime 0.03 0.12 0 0 1 8 26.05 21.9 4 32 14 86
Cefixime 0.25 0.50 nA nA 2 8 nA nA 32 32 nA nA
Ceftibuten 0.03 0.25 nA nA 1 4 nA nA 32 32 nA nA
Cefpodoxime 0.03 0.06 0 0 0.5 2 31.6 18.1 2 4 12 88
Cefotaxime 0.03 0.06 0 0 0.25 0.5 0 0 1 2 17 2
Ceftriaxone 0.03 0.06 0 0 0.25 0.5 0 0 1 2 16 2
Amoxicillin 0.03 0.12 0 0 0.5 1 0 0 4 8 45 40
Amoxicillin-clavulanate 0.03 0.12 0 0 0.5 1 0 0 4 8 45 40
Clarithromycin 0.25 ≥64 4.6 15.4 0.25 ≥64 3.25 39.5 0.5 ≥64 6 45
Azithromycin 0,12 ≥64 9.1 15.4 0.12 ≥64 4.2 38.6 0.5 ≥64 3 47
Levofloxacin 0.12 1 0 0 0.25 2 2.8 2.3 0.5 1 1 3
nA, not available. * Breakpoint as in Lee et al.29
TABLE 2 - in vitro activity of cefditoren and comparative antimicrobial agents against 470 isolates of H. influenzae grouped according to
their susceptibility to ampicillin (b-lactamase-negative or positive).   
Antimicrobial drug MIC (mg/L)
Ampicillin-susceptible Ampicillin-resistant  Ampicillin-resistant  
b-lactamase negative (n= 250) b-lactamase positive (n= 200) b-lactamase negative (n=20)
MiC50 MiC90 %i %R MiC50 MiC90 %i %R MiC50 MiC90 %i %R
Cefditoren* ≤0.015 0.03 0 0 ≤ 0.015 0.03 0 0 ≤ 0.015 0.03 0 0
Cefaclor 1 4 0 0 8 32 21 20 2 4 0 0
Cefuroxime 0.5 2 0 0 1 2 1 1 0.5 2 0 0
Cefixime 0.03 0.25 0 0 0.03 0.06 0 0 0.12 0.25 0 0
Ceftibuten 0.25 0.5 0 0 0.12 0.5 0 0 0.12 0.25 0 0
Cefpodoxime 0.12 0.25 0 0 0.12 0.5 0 0 0.12 0.25 0 0
Cefotaxime ≤0.015 ≤0.015 0 0 ≤0.015 ≤0.015 0 0 ≤ 0.015 0.03 0 0
Ceftriaxone ≤0.015 ≤0.015 0 0 ≤0.015 ≤0.015 0 0 ≤ 0.015 0.03 0 0
Ampicillin 0.25 1.0 0 0 ≥64 ≥64 0 100 4 8 0 100
Amoxi-clavulanate 0.12 2 0 0 0.5 2 0 0 2 4 0 10
Clarithromycin 1 4 0 0 4 8.0 2 1 8 16 25 0
Azithromycin 1 4 0 0 1.0 4 0 0 1 2 0 0
Levofloxacin ≤0.015 ≤0.03 0 0 ≤0.015 ≤0.03 0 0 ≤0.015 ≤0.03 0 0
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TABLE 4 - in vitro activity of cefditoren and comparative antimi-
crobial agents against  225 S. pyogenes. 






Cefditoren 0.03 0.03 nA nA
Cefaclor 0.5 1 nA nA
Cefixime 0.06 0.12 nA nA
Cefuroxime 0.03 0.12 nA nA
Ceftibuten 0.25 0.5 nA nA
Cefpodoxime 0.06 0.12 nA nA
Cefotaxime 0.03 0.06 0 0
Ceftriaxone 0.03 0.06 0 0
Penicillin 0.03 0.06 0 0
Amoxicillin 0.06 0.06 nA nA
Clarithromycin 0.25 ≥64 1.8 23.5
Azithromycin 0.25 ≥64 1.3 24
Levofloxacin 0.25 0.5 0 0
nA, not available.
TABLE 5 - in vitro activity of cefditoren and comparative antimi-
crobial agents against 300 methicillin-susceptible S. aureus. 






Cefditoren* 0.25 0.5 0 0
Cefaclor 2 8 0 0
Cefuroxime 1 2 0 0
Cefixime 16 16 nA nA
Ceftibuten 32 ≥64 nA nA
Cefpodoxime 0.5 4 23 0
Cefotaxime 2 4 0 0
Ceftriaxone 4 4 0 0
Penicillin 1 32 0 87
Amoxi-clavulanate 0.25 1 0 0
Clarithromycin 0.5 32 0 46
Azithromycin 0.5 32 0 46
Levofloxacin 0.25 0.25 2.66 0
nA, not available. * Breakpoint as in Lee et al.29
TABLE 6 - in vitro activity of cefditoren and comparative antimi-
crobial agents against 100 K. pneumoniae. 






Cefditoren* 0.25 2 0 22
Cefaclor 4 32 0 29
Cefuroxime 4 ≥64 2 40
Cefixime 0.12 32 6 28
Ceftibuten 0.12 32 nA nA
Cefpodoxime 0.25 32 0 30
Cefotaxime 0.12 ≥64 0 29
Ceftriaxone 0.25 ≥64 0 18
Amoxi-clavulanate 4 16 5 8
Levofloxacin 0.06 1 0 6
nA, not available. *Breakpoint as in Lee et al.29
TABLE 7 - in vitro activity of cefditoren and comparative antimi-
crobial agents against 100 e. coli. 






Cefditoren 0.03 0.5 nA nA
Cefaclor 2 ≥64 8 21
Cefuroxime 4 16 30 5
Cefixime 0.25 4 9 15
Ceftibuten 0.25 16 nA nA
Cefpodoxime 0.5 16 6 20
Cefotaxime 0.06 2 0 0
Ceftriaxone 0.06 2 0 0
Amoxi-clavulanate 4 32 9 20
Levofloxacin 0.12 8 2 12
nA, not available.
TABLE 3 - in vitro activity of cefditoren and comparative antimicrobial agents against 350 M. catarrhalis grouped according to their b-lac-
tamase production. (CLSi 2006 M45-A) nA, not available. 









% I % R
Cefditoren* ≤ 0.015 ≤ 0.015 0 0 0.12 0.25 0 0
Cefaclor 0.5 1 0 0 1 4 0 0
Cefuroxime 0.25 0.5 0 0 1 8 14 2.8
Cefixime 0.03 0.25 nA nA 0.25 1 nA nA
Ceftibuten 0.06 0.25 nA nA 0.25 0.5 nA nA
Cefpodoxime 0.25 0.5 nA nA 0.25 0.5 nA nA
Cefotaxime ≤ 0.015 ≤ 0.015 0 0 0.25 1 0 0
Ceftriaxone ≤ 0.015 ≤ 0.015 0 0 0.25 1 0 0
Ampicillin 0.12 0.25 nA nA 2 8 nA nA
Amoxi-clavulanate 0.03 0.06 0 0 0.25 1 0 0
Clarithromycin 1 2 5 0 1 4 14 0
Azithromycin 0.5 2 10 0 1 4 12 0
Levofloxacin 0.03 0.06 0 0 ≤ 0.015 0.03 0 0
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DisCUssiOn
The therapy for community-acquired respiratory tract infec-
tions (CARTi) is usually empiric, based on knowledge of the most
probable etiology, and on updated antibiotic susceptibility pro-
files. Antibiotic resistance in respiratory pathogens, especially in
S. pneumoniae, is increasing against important and intensively
used classes of antibiotics in italy as well as other countries, with
the logical consequence of decreased clinical efficacy and in-
creased complications due to incomplete microbiological eradi-
cation.
While epidemiological monitoring of the sensitivity profiles
of S. pneumoniae, H. influenzae and M. catarrhalis, (but also
in S. pyogenes, K. pneumoniae, MssA and e. coli) is un-
doubtedly useful for selecting therapy, the use of new antibiotics
with greater intrinsic efficacy which are able to overcome most
emerging resistance, could be the winning strategy in CARTi.
The data obtained from surveillance studies are necessary, both
for a correct use of antibiotics and to prevent the spread of an-
tibiotic resistance.
One of the greatest problems in evaluating antibiotic activity
in vitro is the lack or nonconformity of the MiC breakpoints. in
the first case, it is difficult to prescribe therapy, and to determine
the correct dose, and in the second case it is difficult to compare
the various antibiotics based on their MiC values. The noncon-
formity of the MiC breakpoints, moreover, makes it impossible
to correctly describe the category of activity of a drug, i.e. sus-
ceptibility or resistance.
A problem of the last few years has been the emergence of
strains of penicillin-resistant S. pneumoniae. This phenomenon
has diminished the intrinsic activity of many beta-lactams, and
necessitated the use of new molecules such as macrolides and flu-
oroquinolones. in the past, macrolides provided an alternative
therapy for patients allergic to beta-lactams, however, they have
become continuously less active due to the increased diffusion
of resistant strains over the years. Quinolones, even if they are
not advisable in pediatric patients, represent a valid alternative to
beta-lactams both in the presence of EsBL-producing strains and
in the presence of beta-lactam- and macrolide-resistant strains.
Our results are in agreement with the most recent interna-
tional literature and confirm that cefditoren is the most active
beta-lactam in vitro against the respiratory pathogen S. pneu-
moniae.11-13,14-20,24-26,30-33 The values of MiC50 and MiC90 found
in the present study are, after one year of commercialization of
cefditoren in italy, almost one dilution lower than those reported
in the multicenter study in italy in 2008.26
S. pneumoniae susceptibilities to oral cephalosporins have
been extremely variable in Europe over the last 3 years. For ex-
ample, in spain, the susceptibility of PRsP to cefpodoxime var-
ied from 92% in 200630 to 64.2% (amoxicillin-sensitive strains)
or 87.7% (amoxicillin-resistant strains) in 200731 and to 97.5%
in 2008.32 susceptibility in italy was 58% in 2008,26 and in this
study 88%. A possible explanation for this disagreement could
come from a recent report by sader14: the activity of cefpo-
doxime against PisP and PRsP is significantly reduced. When
analyzing the literature of the last 10 years in light of the MiC
breakpoints of the CLsi 2008, it can be seen that the MiC90s
are almost the same, while the categories are different. The
same pattern was also found for cefuroxime.26,30,14 it should be
noted that cefixime and ceftibuten are inactive against PisP and
PRsP. Even in the absence of breakpoints, it is obvious that the
high levels of MiC90 (8.4 mg/L for PisP and 32 mg/L for PRsP)
make these oral cephalosporins, on the basis of pharmacoki-
netic and pharmacodynamic considerations23, ineffective from a
clinical point of view. 
Monitoring has shown that there is a trend of an increase in
resistance to levofloxacin in both PssP and PRsP. We found
lower resistance in levofloxacin than that described by seral,34
but higher than that reported by Biedenbach et al.,25 stefani et
al.,26 and Blasi et al.35; the phenomenon of a constant increase
in resistance to levofloxacin has been well documented by Jones
et al.36,37 Our results obtained with the macrolides indicate that
S. pneumoniae is highly resistant to these molecules, inde-
pendently of penicillin resistance, making them unacceptable for
empiric therapy.
TABLE 8 - in vitro activity of cefditoren against 7 respiratory pathogens: comparison (MiC
90




PSSP* PISP* PRSP* H.i. b+* H.i. b-* M.c.b-* M.c.b+* S.pyo* MSSA* Kl.pn.* E.coli* 
(650) (215) (100) (250) (200) (100) (250) (225) (300) (100) (100)
Cefditoren* 0.03 0.5 0.5 0.03 0.03 ≤0.015 0.25 0.03 0.5 2 0.5
Cefaclor 1.0 ≥64 ≥64 4 32 1 4 1 8 32 ≥64
Cefuroxime 0.12 8 32 2 2 0.5 8 0.12 2 ≥64 16
Cefixime 0.50 8 32 0.25 0.06 0.25 1 0.12 16 32 4
Ceftibuten 0.25 4 32 0.5 0.5 0.25 0.5 0.5 ≥64 32 16
Cefpodoxime 0.06 2 4 0.25 0.5 0.5 0.5 0.12 4 32 16
Cefotaxime 0.06 0.5 2 ≤0.015 ≤0.015 ≤0.015 1 0.06 4 ≥64 2
Ceftriaxone 0.06 0.5 2 ≤0.015 ≤0.015 ≤0.015 1 0.06 4 ≥64 2
Penicillin 0.06 32
Ampicllin 1 ≥64 0.25 8
Amoxicillin 0.12 1.0 8 0.06
Amoxicillin-clavulanate 0.12 1.0 8 2 2 0.06 1 1 16 32
Clarithromycin ≥64 ≥64 ≥64 4 8.0 2 4 ≥64 32
Azithromycin ≥64 ≥64 ≥64 4 4 2 4 ≥64 32
Levofloxacin 1.0 2.0 1.0 0.03 0.03 0.06 0.03 0.5 0.25 1 8
*Abbreviations:  penicillin-susceptible S. pneumoniae, penicillin-intermediate S. pneumoniae, penicillin-resistant S. pneumoniae, H. influen-
zae b-lactamase positive, H. influenzae b-lactamase negative, M. cattarhalis b-lactamase negative, M. cattarhalis b-lactamase positive, S. pyo-
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S. pyogenes was susceptible to all beta-lactams studied.
Cefditoren showed the highest intrinsic activity. The resistance
to macrolides is similar to that reported in italy over the last few
years44-46 and is lower than that reported in a previous study.26
The production of beta-lactamases by H. influenzae and M.
catarrhalis did not influence the activity of cefditoren nor the
other beta-lactamase-resistant cephalosporins. The activity of
the antibiotics studied against H. influenzae and BLnAR strains
is similar worldwide and in Europe.26,33,38-43 Cefditoren’s activ-
ity is comparable to that of the injectable cephalosporins tested
and to levofloxacin, while it is higher than that of all the oral
beta-lactams.25-26,38-43 Cefditoren has maintained the same level
of intrinsic strength against H. influenzae shown in the previ-
ous study26, independently of the production of beta-lactamases
or ampicillin resistance. it should be noted that the increase in
resistance to cefaclor compared with the study of 200826 con-
firms the data of Johnson et al.,41 and of more recent observa-
tions.42,43
Our results on the activity of the antibiotics tested against M.
catarrhalis are in agreement with the literature data.11-13,25-
26,29,38,40-43 There has been an increase in MiC values among
beta-lactamase-positive and -negative strains for all the beta-lac-
tams. in agreement with the breakpoints suggested for cefdi-
toren, M. catarrhalis should be considered susceptible. 
The activity of cefditoren against MssA is almost the same
as that of amoxicillin clavulanate and is higher than all the other
beta-lactams while being less than that of levofloxacin.
in conclusion, the confirmation of the wide spectrum of ac-
tivity of cefditoren and its elevated intrinsic strength, its PK/PD
parameters,23 as well as its capacity to overcome much of the
resistance that has become consolidated in some classes of an-
tibiotics that are widely used in empiric therapy for CARTi, al-
lows us to suggest that cefditoren might be included in the
European guidelines among the “first choice antibiotics” for
treatment of community-acquired respiratory tract infections. 
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